As of February 2026, Celgene's annual revenue is estimated to be $21B. The company is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer, with its lead molecule BCMA CAR T used for treating multiple myeloma in phase II clinical study. As a wholly-owned subsidiary integrated into Bristol Myers Squibb's oncology and immunology divisions, Celgene remains a critical driver of BMS's cancer therapeutics portfolio.
Cyborg Score Rationale
Revlimid remains a major revenue driver, though as a subsidiary Celgene operates within BMS's organizational structure. The company maintains robust R&D with multiple clinical-stage candidates and a diversified oncology/immunology pipeline, supporting stable cash flow and strategic positioning in high-margin specialty pharmaceuticals.
Top Insights
BMS acquisition in January 2019 transformed Celgene from independent public company to wholly-owned operating subsidiary, eliminating independent financial reporting and equity trading.
Annual revenue estimated at $21B as of February 2026, positioning Celgene as one of BMS's largest therapeutic franchises.
Pipeline includes BCMA CAR-T in phase II for multiple myeloma, representing next-generation immuno-oncology strategy beyond Revlimid exclusivity.
Operates across oncology, immunology, and hematologic disease markets with geographic presence on six continents; approximately 2,100 employees as of February 2026.
Named Competitors
Kite Pharma — CAR-T cell therapy and oncology focus
Juno Therapeutics — Cell therapy and hematologic malignancy focus
ImmunoACT — Immunotherapy development
Revlimid — Immunomodulatory drug for multiple myeloma
Recent Developments
(January 2019) Acquired by Bristol Myers Squibb in transformative $74B deal
(February 2026) Revenue estimated at $21B annually, underscoring continued commercial performance
Multiple late-stage clinical trials underway expanding treatment indications across hematologic and solid tumors
Open the full interactive Celgene Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.